Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Jazz Pharmaceuticals PLC Stock Research

JAZZ

131.19USD-1.88(-1.41%)Market Closed
Watchlist

Market Summary

USD131.19-1.88
Market Closed
-1.41%

JAZZ Alerts

  • 1 major insider sales recently.
  • Big jump in Earnings (Y/Y)

JAZZ Stock Price

JAZZ RSI Chart

JAZZ Valuation

Market Cap

8.5B

Price/Earnings (Trailing)

-98.43

Price/Sales (Trailing)

2.26

EV/EBITDA

-31.01

Price/Free Cashflow

6.25

JAZZ Price/Sales (Trailing)

JAZZ Profitability

EBT Margin

-8.67%

Return on Equity

-4.69%

Return on Assets

-1.41%

Free Cashflow Yield

16.01%

JAZZ Fundamentals

JAZZ Revenue

Revenue (TTM)

3.8B

Revenue Y/Y

2.62%

Revenue Q/Q

7.22%

JAZZ Earnings

Earnings (TTM)

-86.5M

Earnings Y/Y

201.28%

Earnings Q/Q

50.44%

Price Action

52 Week Range

120.64160.96
(Low)(High)

Last 7 days

0.9%

Last 30 days

-5.8%

Last 90 days

8.6%

Trailing 12 Months

4.6%

JAZZ Financial Health

Current Ratio

3.06

Debt/Equity

1.86

Debt/Cashflow

0.22

JAZZ Investor Care

Shares Dilution (1Y)

2.49%

Diluted EPS (TTM)

-1.59

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for JAZZ

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-01
Patil Neena M
sold
-216,375
144
-1,500
evp & chief legal officer
2023-08-29
Carr Patricia
sold
-20,372
143
-142
svp, chief accounting officer
2023-08-15
Patil Neena M
sold
-104,695
139
-750
evp & chief legal officer
2023-08-14
Smith Mark Douglas
sold
-171,454
138
-1,241
-
2023-08-14
Sohn Catherine A.
sold
-171,455
138
-1,241
-
2023-08-14
Winningham Rick E
sold
-171,455
138
-1,241
-
2023-08-14
Cook Jennifer E.
sold
-171,454
138
-1,241
-
2023-08-14
Carr Patricia
sold
-21,828
138
-158
svp, chief accounting officer
2023-08-14
ENRIGHT PATRICK G
sold
-171,455
138
-1,241
-
2023-08-14
McSharry Heather Ann
sold
-185,685
138
-1,344
-

1–10 of 50

Which funds bought or sold JAZZ recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-20
BARCLAYS PLC
added
35.77
1,467,000
11,222,000
0.01%
2023-09-12
Farther Finance Advisors, LLC
added
11.54
-210
3,595
-%
2023-09-07
ST GERMAIN D J CO INC
new
-
40,166
40,166
-%
2023-09-06
Deep Track Capital, LP
added
4.17
-20,633,500
154,962,000
7.17%
2023-08-28
DELPHI MANAGEMENT INC /MA/
new
-
1,264,000
1,264,000
1.31%
2023-08-22
VIRGINIA RETIREMENT SYSTEMS ET AL
unchanged
-
-2,396,990
13,289,600
0.13%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-4.93
-3,040,980
12,585,300
0.02%
2023-08-21
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
added
2.98
-2,987,000
20,418,000
0.20%
2023-08-21
OSAIC HOLDINGS, INC.
reduced
-10.71
-435,979
1,354,260
-%
2023-08-17
Orion Portfolio Solutions, LLC
reduced
-2.97
-640,844
2,960,780
0.03%

1–10 of 47

Latest Funds Activity

Are funds buying JAZZ calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own JAZZ
No. of Funds

Schedule 13G FIlings of Jazz Pharmaceuticals

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Sep 11, 2023
vanguard group inc
10.26%
6,479,474
SC 13G/A
Feb 09, 2023
vanguard group inc
9.61%
6,050,625
SC 13G/A
Jan 26, 2023
blackrock inc.
10.6%
6,652,382
SC 13G/A
Jan 20, 2023
blackrock inc.
10.6%
6,652,382
SC 13G
Jan 05, 2023
jpmorgan chase & co
4.6%
2,924,604
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Jan 28, 2022
blackrock inc.
10.5%
6,450,368
SC 13G/A
Jan 24, 2022
jpmorgan chase & co
5.2%
3,248,156
SC 13G
Feb 11, 2021
renaissance technologies llc
5.56%
3,099,050
SC 13G/A
Feb 10, 2021
vanguard group inc
8.76%
4,877,893
SC 13G/A

Recent SEC filings of Jazz Pharmaceuticals

View All Filings
Date Filed Form Type Document
Sep 12, 2023
8-K
Current Report
Sep 11, 2023
SC 13G/A
Major Ownership Report
Sep 06, 2023
4
Insider Trading
Sep 01, 2023
144
Notice of Insider Sale Intent
Aug 31, 2023
4
Insider Trading
Aug 29, 2023
144
Notice of Insider Sale Intent
Aug 17, 2023
4
Insider Trading
Aug 15, 2023
4
Insider Trading
Aug 15, 2023
4
Insider Trading
Aug 15, 2023
4
Insider Trading

Peers (Alternatives to Jazz Pharmaceuticals)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
494.8B
29.5B
-0.66% 79.36%
76.16
16.77
1.53% 14.16%
413.2B
97.8B
-4.35% -2.72%
31.65
4.23
2.29% -28.92%
272.8B
58.3B
-4.37% 23.96%
17.88
4.63
2.00% -81.24%
182.9B
77.9B
-10.94% -25.44%
8.52
2.35
-23.04% -26.74%
150.1B
45.2B
-5.70% -15.91%
23.72
3.25
-4.15% 20.34%
MID-CAP
6.5B
-
1.99% 679.20%
-74.1
4.1K
-86.94% 71.24%
4.3B
4.6B
-16.08% -16.44%
-62.89
0.92
6.60% 42.04%
SMALL-CAP
1.6B
634.0M
-6.94% -10.23%
36.56
2.5
0.62% -24.59%
1.6B
627.1M
-7.75% -11.11%
-1.08
2.51
-0.20% -204.67%
858.4M
244.3M
-1.05% 13.25%
4.35
3.51
-39.50% -4.99%
804.1M
109.5M
24.85% -25.44%
-5.6
7.34
-2.66% -32.13%
507.6M
453.3M
136.46% -66.34%
-0.41
1.12
-16.04% 55.90%
469.2M
31.2M
-3.91% -52.16%
-4.46
15.05
407.54% -26.47%
255.1M
54.6M
-17.22% -39.02%
-2.81
4.67
9.39% -179.16%
-
2.2B
- -
-
-
-22.39% 63.59%

Jazz Pharmaceuticals News

Best Stocks
Significant Block Trade of CTLT Shares Shakes Securities Market.
Best Stocks,
71 minutes ago

Returns for JAZZ

Cumulative Returns on JAZZ

4.0%


10-Year Cumulative Returns

0.8%


7-Year Cumulative Returns

-4.4%


5-Year Cumulative Returns

-1.6%


3-Year Cumulative Returns

Risks for JAZZ

What is the probability of a big loss on JAZZ?

78.8%


Probability that Jazz Pharmaceuticals stock will be more than 20% underwater in next one year

49.6%


Probability that Jazz Pharmaceuticals stock will be more than 30% underwater in next one year.

0%


Probability that Jazz Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does JAZZ drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Jazz Pharmaceuticals was unfortunately bought at previous high price.

Drawdowns

Financials for Jazz Pharmaceuticals

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue0.7%3,762,904,0003,738,465,0003,659,374,0003,583,982,0003,481,445,0003,300,378,0003,094,238,0002,863,024,0002,625,797,0002,436,422,0002,363,567,0002,279,790,0002,216,604,0002,188,301,0002,161,761,0002,056,478,0001,988,149,0001,954,495,0001,890,922,0001,850,864,0001,793,346,000
Operating Expenses-------------------1,276,084,0001,279,876,0001,324,681,000
  S&GA Expenses-1.8%1,380,442,0001,406,071,0001,416,967,0001,432,226,0001,437,430,0001,499,988,0001,451,683,0001,300,393,0001,143,966,000906,341,000854,233,000821,336,000792,787,000777,395,000736,942,000684,532,000661,699,000644,264,000683,530,000664,715,000633,365,000
  R&D Expenses---------------299,726,000259,001,000230,306,000224,054,000226,616,000235,954,000232,156,000
EBITDA100.0%--23,078,000-71,811,000-47,336,000-54,661,000-122,761,0003,762,000--714,883,000369,895,000245,457,000191,526,000204,190,000528,702,000650,892,000705,784,000----
EBITDA Margin100.0%--0.01-0.02-0.01-0.02-0.040.00--0.290.160.110.090.090.240.320.35----
Interest Expenses---270,671,000---138,271,000---42,470,000---43,002,000---42,706,000--
Earnings Before Taxes18.8%-263,238,000-324,008,000-372,784,000-77,621,000-85,125,000-242,199,000-112,838,00076,797,000312,571,000620,083,000275,095,000171,057,000117,126,000129,790,000454,302,000578,992,000633,884,000579,199,000529,463,000482,931,000378,868,000
EBT Margin100.0%--0.09-0.10-0.02-0.02-0.07-0.040.030.120.250.120.080.050.060.21------
Net Income44.6%-86,514,000-156,287,000-224,060,000-18,687,000-51,872,000-449,853,000-329,668,000-160,903,00040,164,000518,281,000238,616,000179,194,000133,236,000280,333,000523,367,000608,845,000655,885,000486,308,000447,098,000519,835,000434,045,000
Net Income Margin100.0%--0.04-0.06-0.01-0.01-0.14-0.11-0.060.020.210.100.080.060.130.24------
Free Cashflow-100.0%-1,363,130,0001,242,931,0001,078,126,000920,965,000664,724,000750,866,000765,234,000754,022,000899,334,000884,644,000783,149,000855,045,000810,100,000736,266,000------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets1.9%11,26111,04710,83510,38511,20011,76912,29912,47813,2136,7566,5366,2926,0675,2155,5395,5285,4895,2805,2035,4865,349
  Current Assets8.1%3,0102,7852,6062,5722,5912,5012,6112,6282,9543,1672,8402,5562,3021,5181,6301,5211,3701,3061,2341,4641,307
    Cash Equivalents9.8%1,2821,1688818397114915916728912,0981,058742786702637795638547310499485
  Inventory-2.6%6576757147288629851,0731,1381,25111595.0091.0093.0086.0079.0071.0069.0061.0053.0043.0046.00
  Net PPE----------124128128128130132129127113200198188
  Goodwill1.1%1,7431,7231,6931,5931,6881,7821,8281,8501,888938958937918909920907925920928932936
  Current Liabilities4.0%945909933813705737809735881752654642410396364390369414345341348
    LT Debt, Current0%31.0031.0031.0031.0031.0031.0031.0031.0024924924624433.0033.0033.0033.0033.0033.0033.0033.0033.00
    LT Debt, Non Current-0.1%5,6875,6905,6935,6965,9905,9936,0196,2476,4891,8531,8491,8442,0701,5771,5741,5711,5681,5651,5631,5611,558
Shareholder's Equity5.7%3,5263,3353,0862,7453,2013,6083,9653,9384,1313,7983,6603,3773,1422,8093,1113,0542,9832,7302,7573,0272,870
  Retained Earnings1.1%8128037349749949598308669181,2821,1601,0268787711,0681,1041,0228208461,1281,000
  Additional Paid-In Capital1.9%3,5803,5123,4773,3883,3123,2393,5353,4703,4032,6952,6342,5382,4992,2942,2662,2092,1712,1312,1142,0782,037
Shares Outstanding0.8%64.0063.0063.0063.0062.0062.0062.0061.0059.0056.0056.0056.0055.0056.0056.0057.0057.0057.0058.0060.0060.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations-0.5%1,3771,3841,2721,108964702779787771912900801881847776907791834799785753
  Share Based Compensation3.4%236228222214210205189167144127121116114112111111108106102103105
Cashflow From Investing0.8%-410-413-446-131-163-5,986-5,212-5,128-5,381-210-1,007-1,239-1,119-381-15544.0012.00-176-394-466-477
Cashflow From Financing-37.2%-395-288-529-795-9713,6813,9714,2734,716694528384388-311-293-652-646-561-479-72.66-31.66
  Buy Backs-127-0.000.000.00----7.00147257277329301638639600524119124

JAZZ Income Statement

2023-06-30
CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenues:    
Total revenues$ 957,317$ 932,878$ 1,850,129$ 1,746,599
Operating expenses:    
Cost of product sales (excluding amortization of acquired developed technologies)97,537124,208226,181239,492
Selling, general and administrative340,844366,473638,761675,286
Research and development209,238139,047398,648269,028
Intangible asset amortization152,062148,456301,848320,550
Acquired in-process research and development069,1481,00069,148
Total operating expenses799,681847,3321,566,4381,573,504
Income from operations157,63685,546283,691173,095
Interest expense, net(73,470)(63,189)(147,617)(133,873)
Foreign exchange gain (loss)(2,382)(1,343)811(11,883)
Income before income tax benefit and equity in loss of investees81,78421,014136,88527,339
Income tax benefit(24,323)(16,112)(39,647)(15,576)
Equity in loss of investees1,6692,4612,6746,603
Net income$ 104,438$ 34,665$ 173,858$ 36,312
Net income per ordinary share:    
Basic (in dollars per share)$ 1.63$ 0.56$ 2.73$ 0.58
Diluted (in dollars per share)$ 1.52$ 0.55$ 2.55$ 0.57
Weighted-average ordinary shares used in per share calculations - basic (in shares)63,99162,43663,74462,152
Weighted-average ordinary shares used in per share calculations - diluted (in shares)73,54063,43173,65763,171
Product sales, net    
Revenues:    
Total revenues$ 946,987$ 928,300$ 1,831,206$ 1,738,137
Royalties and contract revenues    
Revenues:    
Total revenues$ 10,330$ 4,578$ 18,923$ 8,462

JAZZ Balance Sheet

2023-06-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 1,282,304$ 881,482
Investments80,0000
Accounts receivable, net of allowances610,389651,493
Inventories657,214714,061
Prepaid expenses107,49091,912
Other current assets272,458267,192
Total current assets3,009,8552,606,140
Property, plant and equipment, net229,264228,050
Operating lease assets69,04073,326
Intangible assets, net5,705,7775,794,437
Goodwill1,742,6751,692,662
Deferred tax assets, net430,086376,247
Deferred financing costs7,8659,254
Other non-current assets65,97855,139
Total assets11,260,54010,835,255
Current liabilities:  
Accounts payable98,42890,758
Accrued liabilities748,304803,255
Current portion of long-term debt31,00031,000
Income taxes payable67,5297,717
Deferred revenue4463
Total current liabilities945,265933,193
Long-term debt, less current portion5,686,6465,693,341
Operating lease liabilities, less current portion65,54771,838
Deferred tax liabilities, net910,724944,337
Other non-current liabilities126,683106,812
Commitments and contingencies (Note 9)
Shareholders’ equity:  
Ordinary shares66
Non-voting euro deferred shares5555
Capital redemption reserve473472
Additional paid-in capital3,580,1153,477,124
Accumulated other comprehensive loss(866,823)(1,125,509)
Retained earnings811,849733,586
Total shareholders’ equity3,525,6753,085,734
Total liabilities and shareholders’ equity$ 11,260,540$ 10,835,255
Bruce C. Cozadd
3200
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.